Dong-A ST and its affiliate Metavia announced on June 9 that they presented research results for the dual-acting GLP-1 (glucagon-like peptide-1)/glucagon obesity treatment "DA-1726" and the MASH (metabolic dysfunction-associated steatohepatitis) treatment "Vanoglipel" (project name DA-1241) at the American Diabetes Association (ADA) Scientific Sessions.


Metavia presented the results of the safety, tolerability, pharmacokinetics, and pharmacodynamics from the high-dose phase 1 clinical trial of DA-1726.

A representative of Dong-A ST is presenting a poster on the research results of the obesity treatment DA-1726 and the MASH treatment Banoglipel at the American Diabetes Association (ADA) conference. Dong-A ST

A representative of Dong-A ST is presenting a poster on the research results of the obesity treatment DA-1726 and the MASH treatment Banoglipel at the American Diabetes Association (ADA) conference. Dong-A ST

View original image

The results demonstrated that DA-1726 showed excellent safety and tolerability in the 48 mg dose group, with no treatment-related serious adverse events or cases of discontinuation reported. Average weight loss was 6.1% on day 26 of administration and 9.1% on day 54. No weight loss plateau was observed through week 8. Waist circumference decreased by an average of 5.8 cm on day 22 and 9.8 cm on day 54, while body mass index (BMI) decreased by 2.3 kg/m² and 3.4 kg/m², respectively. Pharmacokinetic analysis confirmed linear pharmacokinetics and stable systemic exposure with increasing doses.


DA-1726 is a new drug candidate in development as an oxyntomodulin analogue class obesity treatment. It simultaneously targets GLP-1 receptors and glucagon receptors, suppressing appetite, stimulating insulin secretion, and increasing basal metabolic rate in the periphery, ultimately leading to weight loss and improved glycemic control.


Dong-A ST presented preclinical study results evaluating the combined effects of vanoglipel with resmetirom on liver protection and weight loss, as well as the effects of vanoglipel with metformin on glycemic control and weight loss.


In the approximately 16-week combination study of vanoglipel and resmetirom, significant weight loss and liver-protective effects were observed in a MASH mouse model. The combination group experienced a 23.6% reduction in body weight compared to the control group, with fat mass and epididymal fat mass decreasing by 43.5% and 42.1%, respectively. In addition, ALT, a biomarker for liver injury, decreased by 83.5% in the combination group, and histopathological analysis showed improvements in liver fat accumulation, inflammation, and fibrosis-related biomarkers.


This study confirmed the synergistic effects of the combination therapy of vanoglipel (GPR119) and resmetirom (THRβ, thyroid hormone receptor beta), suggesting the potential for a new treatment strategy for MASH.


In the approximately three-week combination study of vanoglipel and metformin, the combination group showed superior glycemic control and weight loss effects compared to the monotherapy group. The combination group saw reductions in non-fasting blood glucose by 28.7% and fasting blood glucose by 22.7%, with body weight decreasing by 16.3% compared to the control group. Fat mass also decreased by 25.6% from baseline. Levels of GLP-1 and PYY (appetite-suppressing hormone) increased 6.4-fold and 1.5-fold, respectively, and food intake was reduced.


Through this study, it was confirmed that the combination therapy of vanoglipel and metformin may provide glycemic control and weight loss benefits by increasing GLP-1 and PYY levels and reducing food intake.


Vanoglipel is a first-in-class oral synthetic drug that acts via the GPR119 mechanism and is under development as a treatment for metabolic dysfunction-associated steatohepatitis and type 2 diabetes. In animal studies, vanoglipel was shown to improve blood glucose and lipid profiles and act directly on the liver to reduce inflammation and fibrosis. In the global phase 2a clinical trial, the drug demonstrated excellent liver-protective and glycemic control effects.


Hyunghun Kim, CEO of Metavia, stated, "Through this ADA presentation, we once again confirmed the differentiated weight loss effect of DA-1726 and the potential for combination therapy with vanoglipel," adding, "Moving forward, we will develop DA-1726 as a differentiated obesity treatment, and vanoglipel as a combination therapy option in the fields of MASH, type 2 diabetes, and other metabolic diseases."



Meanwhile, Metavia serves as the R&D hub for Dong-A Socio Group, responsible for global research and development and commercialization, and is developing obesity treatment DA-1726 and MASH treatment vanoglipel, among others. The company is also presenting its competitiveness and growth strategies to global investors and is continuously seeking opportunities for strategic partnerships.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing